Cyclins and related cyclin-dependent kinases play vital roles in regulating the progression in the cell cycle. Understanding the intrinsic mechanisms of cyclins promises knowledge about cell uncontrolled proliferation and prevention of cancer cells. Therefore, accurate recognition of cyclins is important for the investigation of tumor cells and biomedical engineering. This study proposes a novel sequence-based predictor named TYLER (predicT cYcLin-dEpendent pRoteins) for addressing the long challenge problem of predicting cyclin-dependent proteins (CDPs). We use information theory to compute selectively enriched CDP-related motifs and build the motif-based model. For those proteins without sharing enriched motifs, we compute sequence-derived features and construct machine learning-based models. We optimize the weights of two different models to build a more accurate predictor. We estimate these two types of models by using 5-fold cross-validations on the TRAINING dataset. We prove that the combination of two models and optimization of the corresponding weights promises decent and robust results on both TRAINING and independent TEST dataset. The empirical test demonstrates that TYLER is robust predictor and statistically significantly better than current methods. The runtime assessment reveals TYLER is a high-throughput effective method. We use TYLER to make predictions on the human proteome, and use the results to hypothesize CDPs. The latest experimental verified CDPs and GO analysis proves that some of our novel predictions shall be potential CDPs. TYLER is implemented as a public user-friendly web server at http://www.inforstation.com/webservers/TYLER/. We share all data and source code that used in this research at https://github.com/biocomputinglab/TYLER.git.
Citation: Jian Zhang, Xingchen Liang, Feng Zhou, Bo Li, Yanling Li. TYLER, a fast method that accurately predicts cyclin-dependent proteins by using computation-based motifs and sequence-derived features[J]. Mathematical Biosciences and Engineering, 2021, 18(5): 6410-6429. doi: 10.3934/mbe.2021318
| [1] | Hazhar M. Balaky, Parween Abdulsamad Ismail . Serum resistin, visfatin, IL-17 and IL-23 as novel diagnostic biomarkers for thyroid carcinoma. AIMS Allergy and Immunology, 2025, 9(3): 166-179. doi: 10.3934/Allergy.2025013 |
| [2] | Kazheen Majeed, Hazhmat Ali . Association of low-grade inflammation and oxidative stress with metabolic dysfunction in healthy obese individuals. AIMS Allergy and Immunology, 2025, 9(2): 56-69. doi: 10.3934/Allergy.2025004 |
| [3] | Catalina Marysol Carvajal Gonczi, Fadi Touma, Tina Daigneault, Chelsea Pozzebon, Kelly Burchell-Reyes, Peter J. Darlington . Modulation of IL-17A and IFNγ by β2-adrenergic agonist terbutaline and inverse-agonist nebivolol, influence of ADRB2 polymorphisms. AIMS Allergy and Immunology, 2021, 5(4): 222-239. doi: 10.3934/Allergy.2021017 |
| [4] | Joseph J. Dolence, Hirohito Kita . Allergic sensitization to peanuts is enhanced in mice fed a high-fat diet. AIMS Allergy and Immunology, 2020, 4(4): 88-99. doi: 10.3934/Allergy.2020008 |
| [5] | Ryuta Muromoto, Kenji Oritani, Tadashi Matsuda . Tyk2-mediated homeostatic control by regulating the PGE2-PKA-IL-10 axis. AIMS Allergy and Immunology, 2021, 5(3): 175-183. doi: 10.3934/Allergy.2021013 |
| [6] | Dmitriy I. Sokolov, Anastasia R. Kozyreva, Kseniia L. Markova, Valentina A. Mikhailova, Andrey V. Korenevskii, Yulia P. Miliutina, Olga A. Balabas, Sergey V. Chepanov, Sergey A. Selkov . Microvesicles produced by monocytes affect the phenotype and functions of endothelial cells. AIMS Allergy and Immunology, 2021, 5(3): 135-159. doi: 10.3934/Allergy.2021011 |
| [7] | Shancy Petsel Jacob, Chikkamenahalli Lakshminarayana Lakshmikanth, Thomas M. McIntyre, Gopal Kedihitlu Marathe . Platelet-activating factor and oxidized phosphatidylcholines do not suppress endotoxin-induced pro-inflammatory signaling among human myeloid and endothelial cells. AIMS Allergy and Immunology, 2017, 1(3): 108-123. doi: 10.3934/Allergy.2017.3.108 |
| [8] | Ken S. Rosenthal, Daniel H. Zimmerman . J-LEAPS vaccines elicit antigen specific Th1 responses by promoting maturation of type 1 dendritic cells (DC1). AIMS Allergy and Immunology, 2017, 1(2): 89-100. doi: 10.3934/Allergy.2017.2.89 |
| [9] | Robert Cote, Laura Lynn Eggink, J. Kenneth Hoober . CLEC receptors, endocytosis and calcium signaling. AIMS Allergy and Immunology, 2017, 1(4): 207-231. doi: 10.3934/Allergy.2017.4.207 |
| [10] | Norio Kodaka, Chihiro Nakano, Takeshi Oshio, Hiroto Matsuse . The treatment of severe uncontrolled asthma using biologics. AIMS Allergy and Immunology, 2020, 4(1): 1-13. doi: 10.3934/Allergy.2020001 |
Cyclins and related cyclin-dependent kinases play vital roles in regulating the progression in the cell cycle. Understanding the intrinsic mechanisms of cyclins promises knowledge about cell uncontrolled proliferation and prevention of cancer cells. Therefore, accurate recognition of cyclins is important for the investigation of tumor cells and biomedical engineering. This study proposes a novel sequence-based predictor named TYLER (predicT cYcLin-dEpendent pRoteins) for addressing the long challenge problem of predicting cyclin-dependent proteins (CDPs). We use information theory to compute selectively enriched CDP-related motifs and build the motif-based model. For those proteins without sharing enriched motifs, we compute sequence-derived features and construct machine learning-based models. We optimize the weights of two different models to build a more accurate predictor. We estimate these two types of models by using 5-fold cross-validations on the TRAINING dataset. We prove that the combination of two models and optimization of the corresponding weights promises decent and robust results on both TRAINING and independent TEST dataset. The empirical test demonstrates that TYLER is robust predictor and statistically significantly better than current methods. The runtime assessment reveals TYLER is a high-throughput effective method. We use TYLER to make predictions on the human proteome, and use the results to hypothesize CDPs. The latest experimental verified CDPs and GO analysis proves that some of our novel predictions shall be potential CDPs. TYLER is implemented as a public user-friendly web server at http://www.inforstation.com/webservers/TYLER/. We share all data and source code that used in this research at https://github.com/biocomputinglab/TYLER.git.
| AC | fasting blood glucose |
| BMI | body mass index |
| BUN | blood urea nitrogen |
| Con A | concanavalin A |
| CRE | creatinine |
| HDL-C | high density lipoprotein-cholesterol |
| MS | metabolic syndrome |
| PBMCs | peripheral blood mononuclear cells |
| RELMs | resistin-like molecules |
| RETN | human resistin gene |
| SNPs | single nucleotide polymorphisms |
| SP | systolic pressure |
| T2DM | type 2 diabetes mellitus |
| TG | triglyceride |
The etiology of type 2 diabetes mellitus (T2DM), which affects at least 200 million throughout the world, is not entirely disclosed. Though insulin resistance seems to be a central abnormality, the origin of the impaired insulin action and how it explains the many other clinical symptoms and complications of T2DM still await to be investigated. Obesity, primarily characterized by an increased mass of fat, is a major risk factor which leads to the development of hyperlipidaemia, metabolic syndrome (MS), and T2DM. The adipose tissue is traditionally considered to play a passive role in metabolism by acting as a fat storage reservoir. In addition to being the main energy storage organ, adipocytes are involved actively in maintaining metabolic balance [1,2] by secreting several hormones and cytokines [3]. These adipose derived signaling molecules exert potent metabolic effects to distant organs, which are likely to play a key role in the complex inter-organ communication network to modulate metabolism and energy homeostasis [4,5].
Resistin is a 12.5 kDa cysteine-rich peptide that is secreted from adipocytes in rodents and from macrophages in human [6]. Resistin is a member of the resistin-like molecules (RELMs) with a conserved pattern of 11 cysteine residues at its C-terminus [7]. The postulated roles for resistin include the regulation of glucose homeostasis, adipose tissue mass and inflammation. In murine models, resistin is induced during adipocyte differentiation and its expression is reduced upon treatment with insulin sensitizers. Serum resistin levels are elevated in obese mice, and administration of resistin impairs glucose tolerance in normal mice. Several human studies report serum resistin levels are increased in patients with obesity, insulin resistance, and/or T2DM [8,9,10]. Inflammation is a hyper-resistinemic state in humans, and cytokine induction of resistin may contribute to insulin resistance, obesity, and other inflammatory states [11,12,13].However, the mechanism and importance of increased resistin levels in human MS and T2DM are still not fully illustrated.
The human resistin gene (RETN) is located on chromosome 19p13.3, with several identified single-nucleotide polymorphisms (SNPs) associated with T2DM [14,15]. Two RETN 5'-flanking SNPs are associated with obesity among non-diabetic individuals [16,17]. The RETN -420C>G variants draw much attention and are most extensively investigated. This SNP is the major determinant of the resistin expression and associated with insulin resistance, and possibly with cellular oxidative stress [18]. Mattevi et al. reported that RETN -420C>G is associated with higher mRNA expression in human abdominal subcutaneous fat [19]. Nevertheless, epidemiological studies on the association between the RETN -420C>G SNPs and T2DM risk are conflicting and controversial. Most of the resistin-related studies focus on the investigation of the SNPs in Caucasian or Japanese subjects, relatively few corresponding data in Chinese/Taiwanese populations are reported. Therefore, it is tempting for us to investigate whether RETN SNPs are linked to T2DM in Taiwanese population for determining the ethnic-dependent variations for T2DM development.
Fasting venous blood samples were taken from 244 T2DM patients attending the diabetic clinic in Department of Internal Medicine, Chung Shan Medical University Hospital. Fasting blood samples from 305 non-diabetic control subjects were collected from Physical Check Up Unit. Written informed consent was obtained from all the study subjects after the nature of the procedure was explained. The information of body height, weight, age, fasting blood sugar, renal function index (creatinine [CRE] and blood urea nitrogen [BUN]), etc., was collected and filed for further statistical analysis. The study protocol was approved by the Institutional Review Board of Chung Shan Medical University Hospital.
Peripheral blood was obtained from normal healthy donors, who were receiving no medications nor had any previous history of metabolic disorders, and type 2 diabetic subjects as well. The blood was collected from the antecubital vein in tubes containing EDTA. Samples were immediately processed after blood withdrawal. PBMCs were isolated from buffy coats by layering blood samples onto Ficoll-Paque (Pharmacia Biotech) gradient method in 50 mL conical centrifuge tubes as described [20,21].After centrifugation at 400 × g for 30 min at room temperature, the PBMCs were transferred to a new conical centrifuge tube where the cells were washed twice with phosphate buffered saline.
PBMCs were isolated from whole blood using Ficoll-Paque (Pharmacia Biotech) gradient centrifugation method. After isolation, 2 × 106 PBMCs were cultured in RPMI medium (Hyclone) containing 10% FBS (GIBCO). After 24 h of 10 μg/mL concanavalin A (Con A, Sigma) treatment, secreted resitin levels by the activated PBMCs were determined using ELISA kit (R & D).
Genomic DNA was extracted from PBMCs using commercially available kit. The 5'-flanking region of the RETN gene was amplified by PCR reaction containing 100 ng of genomic DNA, 12.5 pmol of each primer (5'-TGTCATTCTCACCCAGAGACA-3' and 5'-TGGGCTCAGCTAACCAAATC-3'), 1 unit of Taq DNA polymerase and 125 μM dNTP in a total volume of 25 μL, using a PCR thermalcycler. DNA products after PCR amplification were digested using restriction enzyme Bpi I to detect the -420C>G polymorphism, followed by separation in 12% polyacrylamide gel.
Data analysis started with descriptive statistics, including mean and standard deviation for continuous variables, and frequency for categorical variables. If necessary, natural logarithm transformation was used to enhance normality for blood biochemistry parameters with skewed distribution. Student's t test was applied for comparisons of age, body mass index (BMI), and each of the blood biochemistry parameters between T2DM subjects and controls, and Chi-square test for comparing frequencies of different genotypes and sex between groups. Moreover, one-way analysis of variance was applied to compare means of respective blood biochemistry parameters among subjects with different RETN genotypes. Finally, multiple linear regression analysis was used to assess the associations between RETN genotypes and each of the biochemistry parameters, with adjustment for diabetes status, age, and sex. An alpha level of 0.05 was used for all statistical tests.
Our study aimed at investigating the distribution of the RETN -420 SNPs among control and type 2 diabetic subjects to examine the possible correlation between RETN genetic polymorphisms and T2DM in Taiwanese population.
| Item | Normal range | Study subjects | P | |
| Control (n = 244) | T2DM (n = 305) | |||
| Male/female | 156/88 | 159/146 | 0.003 | |
| Age (years) | 51.5 ± 13.3 | 57.6 ± 11.2 | < 0.001 | |
| BMI (kg/m2) | 25.5 ± 5.5 | 25.4 ± 5.5 | 0.078 | |
| Fasting plasma glucose (AC) | 70–110 mg/dl | 105.2 ± 40.3 | 176.4 ± 70.4 | < 0.001 |
| Blood urea nitrogen (BUN) | 7–21 mg/dl | 15.0 ± 4.8 | 17.2 ± 7.8 | < 0.001 |
| Creatinine | 0.6–1.4 mg/dl | 1.1 ± 0.3 | 1.0 ± 0.5 | 0.066 |
| Systolic pressure (SP) | 120–140 mmHg | 123.7 ± 17.6 | 133.5 ± 18.6 | < 0.001 |
| Diastolic pressure (DP) | 70–90 mmHg | 78.4 ± 9.6 | 79.2 ± 11.5 | 0.521 |
| Cholesterol (CHO) | 125–240 mg/dl | 193.0 ± 37.5 | 198.8 ± 46.8 | 0.055 |
| High density lipoprotein-cholesterol (HDL-C) | > 35 mg/dl | 55.5 ± 38.2 | 47.8 ± 13.9 | < 0.001 |
| Triglyceride (TG) | 20–200 mg/dl | 150.7 ± 129.6 | 183.6 ± 129.6 | 0.004 |
| *Student's t test. †Data are presented as mean ± standard deviation. | ||||
DownLoad: CSVData regarding biochemical parameters of recruited subjects, including the healthy control individuals and diabetic patients, were listed in Table 1. Among the biochemical parameters examined, significant differences were observed in fasting blood glucose (AC; 105.2 ± 40.3 v.s 176.4 ± 70.4 mg/dL, p < 0.001), BUN (15.0 ± 4.8 v.s 17.2 ± 7.8 mg/dL, p < 0.001), systolic pressure (SP, 123.7 ± 17.6 v.s 133.5 ± 18.6 mmHg, p < 0.001), high density lipoprotein-cholesterol (HDL-C; 55.5 ± 38.2 v.s 47.8 ± 13.9 mg/dL, p < 0.001) and triglyceride (TG; 150.7 ± 129.6 v.s 183.6 ± 129.6 mg/dL, p = 0.004) under fasting conditions between patients and controls.
| Genotype/allele | Resistin -420C>G SNPs | P | |
| Control (n = 244) | T2DM (n = 305) | ||
| C/C | 70 (28.7%) | 124 (40.6%) | 0.01 |
| C/G | 127 (52.0%) | 139 (45.6%) | |
| G/G | 47 (19.3%) | 42 (13.8%) | |
| C | 267 (54.7%) | 387 (63.4%) | 0.002 |
| G | 221 (45.3%) | 223 (36.6%) | |
DownLoad: CSVResults regarding the distribution of the RETN -420 SNPs in recruited subjects were summarized in Table 2. Among the 244 non-diabetic control individuals, 70 (28.7%), 127 (52.0%) and 47 (19.3%) subjects carried C/C, C/G and G/G genotype, respectively; while the corresponding number in T2DM patients was 124 (40.6%), 139 (45.6%) and 42 (13.8%). Significant difference in distribution of RETN -420C>G genotypes between T2DM and control subjects was observed (p = 0.01). In addition, the prevalence of RETN -420 C and G allele in control individuals was 54.7% and 45.3%, respectively; and that in T2DM counterpart was 63.4% and 36.6%. Significant difference in the distribution of RETN alleles between diabetic patients and control subjects was also observed (p = 0.002). The above observations demonstrate that the RETN -420 SNPs are associated with T2DM subjects in Taiwanese population.
In addition to the significant association between RETN -420C>G genotypes with T2DM, we further investigated the correlation between the SNPs and biochemical parameters by stratifying the study subjects according to the criteria of whether their test results were within or beyond the normal range (Table 3). No significant association between the biochemical data and RETN -420 SNPs was found.
| Item | Range | Control | T2DM | ||||||||
| n | C/C n (%) | C/G n (%) | G/G n (%) | P | n | C/C n (%) | C/G n (%) | G/G n (%) | P | ||
| BMI | ≥25 | 97 | 34 (35.1%) | 49 (50.5%) | 14 (14.4%) | 0.073 | 74 | 28 (37.8%) | 38 (51.4%) | 8 (10.8%) | 0.280 |
| < 25 | 124 | 29 (23.4%) | 65 (52.4%) | 30 (24.2%) | 54 | 23 (42.6%) | 21 (38.9%) | 10 (18.5%) | |||
| SP | ≥140 | 45 | 9 (20%) | 29 (64.4%) | 7 (15.6%) | 0.162 | 37 | 13 (35.1%) | 18 (48.7%) | 6 (16.2%) | 0.794 |
| < 140 | 175 | 53 (30.3%) | 85 (48.6%) | 37 (21.1%) | 57 | 24 (42.1%) | 25 (43.9%) | 8 (14%) | |||
| DP | ≥90 | 33 | 8 (24.2%) | 18 (54.6%) | 7 (21.2%) | 0.862 | 25 | 10 (40%) | 13 (52%) | 2 (8%) | 0.501 |
| < 90 | 187 | 54 (28.9%) | 96 (51.3%) | 37 (19.8%) | 69 | 27 (39.1%) | 30 (43.5%) | 12 (17.4%) | |||
| AC | ≥110 | 27 | 7 (26%) | 12 (44.4%) | 8 (29.6%) | 0.399 | 186 | 77 (41.4%) | 80 (43%) | 29 (15.6%) | 0.186 |
| < 110 | 194 | 56 (28.8%) | 102 (52.6%) | 36 (18.6%) | 19 | 4 (21.1%) | 10 (52.6%) | 5 (26.3%) | |||
| BUN | ≥25 | 2 | 0 | 2 (100%) | 0 | 0.388 | 21 | 7 (33.3%) | 11 (52.4%) | 3 (14.3%) | 0.634 |
| < 25 | 219 | 63 (28.8%) | 112 (51.1%) | 44 (20.1%) | 132 | 57 (43.2%) | 55 (41.7%) | 20 (15.1%) | |||
| CRE | ≥1.4 | 17 | 1 (5.9%) | 12 (70.6%) | 4 (23.5%) | 0.092 | 27 | 11 (40.8%) | 9 (33.3%) | 7 (25.9%) | 0.256 |
| < 1.4 | 203 | 62 (30.5%) | 101 (49.8%) | 40 (19.7%) | 163 | 63 (38.7%) | 76 (46.6%) | 24 (14.7%) | |||
| CHO | ≥240 | 21 | 4 (19.1%) | 14 (66.7%) | 3 (14.2%) | 0.358 | 24 | 13 (54.2%) | 6 (25%) | 5 (20.8%) | 0.103 |
| < 240 | 199 | 58 (29.1%) | 100 (50.3%) | 41 (20.6%) | 175 | 64 (36.6%) | 84 (48%) | 27 (15.4%) | |||
| HDL-C | > 35 | 196 | 60 (30.6%) | 100 (51%) | 36 (18.4%) | 0.088 | 131 | 52 (39.7%) | 58 (44.3%) | 21 (16%) | 0.390 |
| ≤35 | 25 | 3 (12%) | 14 (56%) | 8 (32%) | 37 | 12 (32.4%) | 21 (56.8%) | 4 (10.8%) | |||
| TG | ≥200 | 51 | 14 (27.5%) | 24 (47.1%) | 13 (25.4%) | 0.521 | 59 | 26 (44.1%) | 24 (40.7%) | 9 (15.2%) | 0.557 |
| < 200 | 169 | 48 (28.4%) | 90 (53.3%) | 31 (18.3%) | 139 | 50 (36%) | 66 (47.5%) | 23 (16.5%) | |||
DownLoad: CSV| Genotype | Control | T2DM | P | ||
| n (107) | Resistin (ng/mL) | n (58) | Resistin (ng/mL) | ||
| C/C | 16 | 2.50 ± 0.44 | 22 | 3.95 ± 0.80 | 0.044 |
| C/G | 54 | 3.94 ± 0.53 | 24 | 4.31 ± 0.88 | |
| G/G | 37 | 2.56 ± 0.43 | 12 | 4.88 ± 2.31 | |
| Resistin levels secreted from the ConA-activated PBMCs from 107 control and 58 diabetic subjects were analyzed. | |||||
DownLoad: CSVTo further investigate the association of resistin and T2DM, resistin levels produced by ConA-activated PBMCs from 107 control and 58 T2DM study subjects were determined. The results showed that while no significant difference between the resistin levels and RETN -420 genotypes was observed, the secretory resisitn levels by Con A-stimulated PBMCs from T2DM were significantly higher than that from control subjects.
Most of the identified RETN SNPs are mapped to the non-coding region, with rs1862513 at position -420 attracts much attention and thus is most widely studied SNPs among different ethnic populations. In addition to the association between RETN -420 SNPs with insulin resistance [15], obesity [15,17,19] and T2DM [22,23], the RETN -420 G allele is associated with stronger promoter activity [22], higher abdominal fat resistin mRNA levels and plasma resistin concentrations [6,14]. This G allele is also suggested to be an independent predictor for blood glucose deterioration in a Chinese population [24]. Despite the association between RETN SNPs with plasma resistin levels and insulin resistance [25], conflicting results are reported. While a meta-analysis indicates that individuals carrying homozygous -420 G allele have a 30% increased odds of developing T2DM [22], another concludes no significant association is observed between RETN -420C>G and T2DM risk [26]. Additionally, even varying results are identified in different subjects sampling within the same ethnic origin, possibly due to the difference of patients' clinical profiles or statistical strategies.
Most of the recruited subjects regarding RETN genetic studies are populations from Japanese and Caucasian origins. As mentioned above, discrepancies are reported and the associations between RETN genotypes and diabetic onset are therefore controversial. To the best of our knowledge, only 1 study regarding the resistin +62G>A genotype in Taiwanese subjects is documented [27]. Therefore, it is tempting for us to investigate the most profoundly studied RETN -420C>G SNPs in Taiwanese diabetic patients for examining the putative correlation and involvement of this SNP in our population. Our results indicate that not only the distribution of RETN -420C>G genotypes but also G allele is significantly different between diabetic and control subjects. Nevertheless, no significant association between the subjects' biochemical data and RETN -420 SNPs is found. Although focusing on different RETN SNPs, our data support the report from Tan et al, in which resistin gene polymorphism is an independent factor associated with T2DM [27].
It is intriguing to consider the contribution of RETN -420 SNPs from a general prospective by analyzing the distribution of the variants among different ethnic populations. Upon comparing the overall frequency of RETN -420C>G variants among populations with different ethnic origins, several interesting phenomena were observed. First of all, the frequencies of RETN -420 G allele in Asian population (>30%) are higher than Caucasian subjects (Table 5). The observation supports the finding from Chi et al that the frequency of RETN -420 G allele in Chinese population is significantly different from those in European population [28]. Secondly, among the Asian subjects with higher G allele frequency, this SNP is associated with T2DM onset in Japanese and Taiwanese population, but not in the Caucasian populations (Table 5). Thirdly, the RETN genotypes are reported to be associated with circulatory resistin levels in most of the studies from Asian countries (Table 6).
| Population/ Subjects | n | SNP | allele | Association | Ref. | |||
| C/C | C/G | G/G | C | G | ||||
| Finnish | ||||||||
| Control | 409 | 599 (73.2%) | 219 (26.7%) | insulin resistance | [17] | |||
| T2DM | 781 | 1141 (73.0%) | 423 (27.0%) | |||||
| Canadian | ||||||||
| Control | 411 | 212 (51.6%) | 169 (41.1%) | 30 (7.3%) | 593 (72.1%) | 229 (27.9%) | BMI | [15] |
| T2DM | 179 | 90 (50.3%) | 78 (43.6%) | 11 (6.1%) | 258 (72.1%) | 100 (27.9%) | ||
| Scandinavian | ||||||||
| Control | 433 | 236 (54.5%) | 156 (36.0%) | 41 (9.5%) | 628 (72.5%) | 238 (27.5%) | [15] | |
| T2DM | 452 | 238 (52.7%) | 170 (37.6%) | 44 (9.7%) | 646 (71.5%) | 258 (28.5%) | ||
| European-derived Brazilian | ||||||||
| Control | 251 | 125 (49.8%) | 101 (40.2%) | 25 (10.0%) | 351 (69.9%) | 151 (30.1%) | BMI waist circumference | [19] |
| Overweight & obese | 334 | 182 (54.5%) | 122 (36.5%) | 30 (9.0%) | 486 (72.8%) | 182 (27.2%) | ||
| Korean | ||||||||
| Control | 173 | 89 (51.5%) | 63 (36.4%) | 21 (12.1%) | 241 (69.7%) | 105 (30.3%) | resistin level | [6] |
| T2DM | 411 | 194 (47.2%) | 163 (39.7%) | 54 (13.1%) | 551 (67.0%) | 271 (33.0%) | ||
| Japanese | ||||||||
| Control | 564 | 247 (43.8%) | 269 (47.7%) | 48 (8.5%) | 763 (67.6%) | 365 (32.4%) | T2DM | [22] |
| T2DM | 546 | 216 (39.6%) | 254 (46.5%) | 76 (13.9%) | 686 (62.8%) | 406 (37.2%) | ||
| Japanese | ||||||||
| Control | 2,502 | 1,080 (43.2%) | 1,123 (44.9%) | 299 (11.9%) | 3,283 (65.6%) | 1,721 (34.4%) | young T2DM | [23] |
| T2DM | 2,610 | 1,169 (44.9%) | 1,144 (43.8%) | 297 (11.4%) | 3,482 (66.7%) | 1,738 (33.3%) | ||
| Taiwanese | ||||||||
| Control | 244 | 70 (28.7%) | 127 (52.0%) | 47 (19.3%) | 267 (54.7%) | 221 (45.3%) | T2DM resistin level | this study |
| T2DM | 305 | 124 (40.6%) | 139 (45.6%) | 42 (13.8%) | 387 (63.4%) | 223 (36.6%) | ||
| Numbers in parenthesis of population indicated the number of study subjects in each study. | ||||||||
DownLoad: CSV| No | Population/Subjects | n | SNP | Association | Ref. | ||
| Serum resistin | T2DM | others | |||||
| Meta-analysis | |||||||
| 1 | Control | 5,959 | -420C>G | – | – | [26] | |
| T2DM | 5,935 | ||||||
| 2 | Control | 529 | -638G>A | + | – | [29] | |
| T2DM | 529 | -420C>G | – | – | |||
| Chinese | |||||||
| 3 | Control | 370 | -420C>G | – | [28] | ||
| T2DM | 318 | -394C>G | – | ||||
| 4 | Non-diabetic subjects | 624 | -420C>G | + | insulin resistance | [24] | |
| +62G>A | glycemia | ||||||
| Japanese | |||||||
| 5 | Control | 286 | -420C>G | + | stroke | [30] | |
| T2DM | 349 | ||||||
| 6 | Community subjects | 2,077 | -420C>G | + | synergistically with PPAR P12A | [31] | |
| 7 | Control | 2,502 | -420C>G | – | young T2DM onset | [23] | |
| T2DM | 2,610 | ||||||
| 8 | Community subjects | 2,078 | -420C>G | + | insulin resistance, low HDL high CRP | [37] | |
| 9 | Obese | 60 | -638G>A | + | [38] | ||
| -420C>G | + | ||||||
| 10 | controls | 157 | -420C>G | + | [32] | ||
| T2DM | 198 | ||||||
| 11 | Control | 406 | -420C>G | + | + | [22] | |
| T2DM | 397 | ||||||
| Thais | |||||||
| 12 | Control | 105 | -420C>G | – | [39] | ||
| T2DM | 95 | +299G>A | + | + | |||
| Korean | |||||||
| 13 | Control | 173 | -537A>C | + | [6] | ||
| T2DM | 411 | -420C>G | + | ||||
DownLoad: CSVSeveral contradictory facts can be raised according to the above observations. First of all, several reports reveal that resistin levels are significantly increased in a genotype-dependent manner based on the RETN -420 polymorphisms. Subjects carrying RETN -420 G/G genotype had the highest circulating resistin levels, followed by C/G-and C/C-carrying individuals [29,30,31]. The RETN -420 G/G genotype increases T2DM susceptibility by enhancing its promoter activity [32]. On the contrary, no significant difference between the resistin levels and the RETN -420 genotypes is found in the present study. Nevertheless, our results show that the resistin levels from T2DM subjects are significantly higher than the control subgroup (Table 4). The reason behinds this discrepancy is perhaps that we examined secretory resistin from ConA-activated PBMCs, since we suggest that the plasma resistin levels would be affected by multiple unidentified factors which are possible to deviate the data and corresponding conclusions. In addition, although it is unlikely that RETN is the only gene carrying susceptibility for T2DM development, the other paradox is that the diabetic prevalence of Asian populations with higher frequency of the susceptible G allele is much lower than Caucasian [28]. We previously characterized that certain SNPs identified to be associated with insulin sensitivity in Caucasians are unlikely to be involved in Taiwanese T2DM development [33,34,35,36]. Taken together, unique genetic characteristics and distinct factors may play roles in the diabetic pathogenesis among subjects from different racial origins. A given population may have unique protective elements in the genetic reservoir despite the high prevalence of disease-susceptible alleles. Therefore, the possibility of differential protective genetic factors related to a particular ethnicity may lead to the conflicting results among studies.
This study reports the association between RETN -420 polymorphisms and diabetic incidence in Taiwanese population. Our results suggest that RETN -420C>G SNPs are associated with diabetic susceptibility, but not subjects' clinical profiles. Investigation of RETN SNPs in T2DM patients from various ethnic populations is crucial and will contribute to the understanding of this gene in the diabetic etiology. The present results provide clues to elucidate the contribution of genetic heterogeneity for diabetic development.
This work was supported in part by grants from Ministry of Science and Technology (MOST-105-2320-B-241-005 and 106-2314-B-010-032), Taiwan.
All authors declare no conflicts of interest in this paper.
| [1] | S. Lim, P. Kaldis, Cdks, cyclins and CKIs: roles beyond cell cycle regulation, Development, 140 (2013), 3079-3093. |
| [2] |
M. C. Horne, G. L. Goolsby, K. L. Donaldson, D. Tran, M. Neubauer, A. F. Wahl, Cyclin G1 and cyclin G2 comprise a new family of cyclins with contrasting tissue-specific and cell cycle-regulated expression, J. Biol. Chem., 271 (1996), 6050-6061. doi: 10.1074/jbc.271.11.6050
|
| [3] | D. Fisher, Control of DNA replication by cyclin-dependent kinases in development, Results Probl. Cell Differ., 53 (2011), 201-217. |
| [4] |
N. Bouftas, K. Wassmann, Cycling through mammalian meiosis: B-type cyclins in oocytes, Cell Cycle, 18 (2019), 1537-1548. doi: 10.1080/15384101.2019.1632139
|
| [5] |
G. Zheng, H. Yu, Cyclin a turns on bora to light the path to mitosis, Dev. Cell, 45 (2018), 542-543. doi: 10.1016/j.devcel.2018.05.017
|
| [6] |
A. W. Murray, Recycling the cell cycle: cyclins revisited, Cell, 116 (2004), 221-234. doi: 10.1016/S0092-8674(03)01080-8
|
| [7] |
D. W. Stacey, Cyclin D1 serves as a cell cycle regulatory switch in actively proliferating cells, Curr. Opin. Cell Biol., 15 (2003), 158-163. doi: 10.1016/S0955-0674(03)00008-5
|
| [8] | D. J. Wood, J. A. Endicott, Structural insights into the functional diversity of the CDK-cyclin family, Open Biol., 8 (2018), 180112. |
| [9] | M. Örd, K. Möll, A. Agerova, R. Kivi, I. Faustova, R. Venta, et al., Multisite phosphorylation code of CDK, Nat. Struct. Mol. Biol., 26 (2019), 649-658. |
| [10] | P. Gutiérrez-Escribano, P. Nurse, A single cyclin-CDK complex is sufficient for both mitotic and meiotic progression in fission yeast, Nat. Commun., 6 (2015), 1-13. |
| [11] | C. Gérard, A. Goldbeter, From quiescence to proliferation: Cdk oscillations drive the mammalian cell cycle, Front. Physiol., 3 (2012), 413. |
| [12] | G. Bertoni, Cell cycle regulation by chlamydomonas cyclin-dependent protein kinases, Plant Cell, 30 (2018), 271. |
| [13] | M. Stamatakos, V. Palla, I. Karaiskos, K. Xiromeritis, I. Alexiou, I. Pateras, et al., Cell cyclins: triggering elements of cancer or not?, World J. Surg. Oncol., 8 (2010), 111. |
| [14] | L. C. Leal-Esteban, L. Fajas, Cell cycle regulators in cancer cell metabolism, Biochem. Biophys. Acta, Mol. Basis Dis., 1866 (2020), 165715. |
| [15] |
E. A. Musgrove, C. E. Caldon, J. Barraclough, A. Stone, R. L. Sutherland, Cyclin D as a therapeutic target in cancer, Nat. Rev. Cancer, 11 (2011), 558-572. doi: 10.1038/nrc3090
|
| [16] | Y. Geng, W. Michowski, J. M. Chick, Y. E. Wang, M. E. Jecrois, K. E. Sweeney, et al., Kinase-independent function of E-type cyclins in liver cancer, Proc. Nat. Acad. Sci. U. S. A., 115 (2018), 1015-1020. |
| [17] | R. V. Dross, P. J. Browning, J. C. Pelling, Do truncated cyclins contribute to aberrant cyclin expression in cancer?, Cell Cycle, 5 (2006): 472-477. |
| [18] | C. Sanchez-Martinez, L. M. Gelbert, M. J. Lallena, A. de Dios, Cyclin dependent kinase (CDK) inhibitors as anticancer drugs, Bioorg. Med. Chem. Lett., 25 (2015), 3420-3435. |
| [19] | W. Rozpędek, D. Pytel, A. Nowak-Zduńczyk, D. Lewko, R. Wojtczak, J. A. Diehl, et al., Breaking the DNA damage response via serine/threonine kinase inhibitors to improve cancer treatment. Curr. Med. Chem., 26 (2019), 1425-1445. |
| [20] | J. A. Diehl, Cycling to cancer with cyclin D1, Cancer Biol. Ther., 1 (2002), 226-231. |
| [21] |
J. K. Kim, J. A. Diehl, Nuclear cyclin D1: an oncogenic driver in human cancer, J. Cell Physiol., 220 (2009), 292-296. doi: 10.1002/jcp.21791
|
| [22] | M. K. Kalita, U. K. Nandal, A. Pattnaik, A. Sivalingam, G. Ramasamy, M. Kumar, CyclinPred: a SVM-based method for predicting cyclin protein sequences, PLoS One, 3 (2008), e2605. |
| [23] | H. Mohabatkar, Prediction of cyclin proteins using Chou's pseudo amino acid composition. Protein Pept. Lett., 17 (2010), 1207-1214. |
| [24] | Saxena, K. Pant, B. Pant, N. Adlakha, Hybrid based SVM model for prediction of CDKs and cyclins, in 2010 The 2nd International Conference on Computer and Automation Engineering (ICCAE), 5 (2010), 504-508. |
| [25] | J. Ramana, D. Gupta, Machine learning methods for prediction of CDK-inhibitors, Plos One, 5 (2010), e13357. |
| [26] |
P. Loyer, J. H. Trembley, Roles of CDK/Cyclin complexes in transcription and pre-mRNA splicing: Cyclins L and CDK11 at the cross-roads of cell cycle and regulation of gene expression, Semin. Cell Dev. Biol., 107 (2020), 36-45. doi: 10.1016/j.semcdb.2020.04.016
|
| [27] |
S. Bandyopadhyay, S. Bhaduri, M. Örd, N. E. Davey, M. Loog, P. M. Pryciak, Comprehensive analysis of G1 cyclin docking motif sequences that control CDK regulatory potency in vivo, Curr. Biol., 30 (2020), 4454-4466. doi: 10.1016/j.cub.2020.08.099
|
| [28] |
D. Y. Takeda, J. A. Wohlschlegel, A. Dutta, A bipartite substrate recognition motif for cyclin-dependent kinases, J. Biol. Chem., 276 (2001), 1993-1997. doi: 10.1074/jbc.M005719200
|
| [29] |
J. A. Wohlschlegel, B. T. Dwyer, D. Y. Takeda, A. Dutta, Mutational analysis of the Cy motif from p21 reveals sequence degeneracy and specificity for different cyclin-dependent kinases, Mol. Cell. Biol., 21 (2001), 4868-4874. doi: 10.1128/MCB.21.15.4868-4874.2001
|
| [30] | C. S. Gelais, S. H. Kim, V. V. Maksimova, O. Buzovetsky, K. M. Knecht, C. Shepard, et al., A cyclin-binding motif in human SAMHD1 is required for its HIV-1 restriction, dNTPase activity, tetramer formation, and efficient phosphorylation, J. Virol., 92 (2018), e01787-17. |
| [31] | D. J. Wood, J. A. Endicott, Structural insights into the functional diversity of the CDK-cyclin family, Open Biol., 8 (2018), 180112. |
| [32] | M. W. Landis, N. E. Brown, G. L. Baker, A. Shifrin, M. Das, Y. Geng, et al., The LxCxE pRb interaction domain of cyclin D1 is dispensable for murine development, Cancer Res., 67 (2007), 7613-7620. |
| [33] |
I. Quilis, J. C. Igual, A comparative study of the degradation of yeast cyclins Cln1 and Cln2, FEBS Open Bio., 7 (2017), 74-87. doi: 10.1002/2211-5463.12157
|
| [34] | M. Wei, Q. He, Z. Yang, Z. Wang, Q. Zhang, B. Liu, et al., Integrity of the LXXLL motif in Stat6 is required for the inhibition of breast cancer cell growth and enhancement of differentiation in the context of progesterone, BMC Cancer, 14 (2014), 1-17. |
| [35] | A. Bateman, UniProt: a worldwide hub of protein knowledge, Nucleic Acids Res., 47 (2019), D506-d515. |
| [36] | S. F. Altschul, T. L. Madden, A. A. Schäffer, J. Zhang, Z. Zhang, W. Miller, et al., Gapped BLAST and PSI-BLAST: a new generation of protein database search programs, Nucleic Acids Res., 25 (1997), 3389-3402. |
| [37] |
C. E. Grant, T. L. Bailey, W. S. Noble, FIMO: scanning for occurrences of a given motif, Bioinformatics, 27 (2011), 1017-1018. doi: 10.1093/bioinformatics/btr064
|
| [38] | M. U. Johansson, V. Zoete, O. Michielin, N. Guex, Defining and searching for structural motifs using DeepView/Swiss-PdbViewer, BMC Bioinf., 13 (2012), 1-11. |
| [39] | J. Zhang, H. Chai, G. Yang, Z. Ma, Prediction of bioluminescent proteins by using sequence-derived features and lineage-specific scheme, BMC Bioinf., 18 (2017), 1-13. |
| [40] |
H. Chai, J. Zhang, Identification of mammalian enzymatic proteins based on sequence-derived features and species-specific scheme, IEEE Access, 6 (2018), 8452-8458. doi: 10.1109/ACCESS.2018.2798284
|
| [41] | J. Zhang, H. Chai, S. Guo, H. Guo, Y. Li, High-throughput identification of mammalian secreted proteins using species-specific scheme and application to human proteome, Molecular, 23 (2018), 1448. |
| [42] | J. Zhang, Y. Zhang, Z. Ma, In-silico prediction of human secretory proteins in plasma based on discrete firefly optimization and application to Cancer biomarkers identification, Front. Genet., 10 (2019), 542. |
| [43] |
K. V. Gunbin, V. V. Suslov, I. I. Turnaev, D. A. Afonnikov, N. A. Kolchanov, Molecular evolution of cyclin proteins in animals and fungi, BMC Evol. Biol., 11 (2011), 1-20. doi: 10.1186/1471-2148-11-1
|
| [44] |
J. Zhang, Y. Zhang, Y. Li, S. Guo, G. Yang, Identification of cancer biomarkers in human body fluids by using enhanced physicochemical-incorporated evolutionary conservation scheme, Curr. Trends Med. Chem., 20 (2020), 1888-1897. doi: 10.2174/1568026620666200710100743
|
| [45] | X. Zhao, J. Zhang, Q. Ning, P. Sun, Z. Ma, M. Yin, Identification of protein pupylation sites using bi-profile Bayes feature extraction and ensemble learning, Math. Probl. Eng., 2013 (2013). |
| [46] |
H. Chai, J. Zhang, G. Yang, Z. Ma, An evolution-based DNA-binding residue predictor using a dynamic query-driven learning scheme, Mol. BioSyst., 12 (2016), 3643-3650. doi: 10.1039/C6MB00626D
|
| [47] |
M. Hauser, M. Steinegger, J. Söding, MMseqs software suite for fast and deep clustering and searching of large protein sequence sets, Bioinformatics, 32 (2016), 1323-1330. doi: 10.1093/bioinformatics/btw006
|
| [48] |
L. Khalatbari, M. R. Kangavari, S. Hosseini, H. Yin, N. M. Cheung, MCP: a multi-component learning machine to predict protein secondary structure, Comput. Biol. Med., 110 (2019), 144-155. doi: 10.1016/j.compbiomed.2019.04.040
|
| [49] | M. Malumbres, Cyclin-dependent kinases, Genome Biol., 15 (2014), 1-10. |
| [50] | C. Ratineau, M. W. Petry, H. Mutoh, A. B. Leiter, Cyclin D1 represses the basic helix-loop-helix transcription factor, BETA2/NeuroD, J. Biol. Chem., 277 (2002), 8847-8853. |
| [51] | U. K. Bhawal, F. Sato, Y. Arakawa, K. Fujimoto, T. Kawamoto, K. Tanimoto, et al., Basic helix‐loop‐helix transcription factor DEC1 negatively regulates cyclin D1, J. Pathol., 224 (2011), 420-429. |
| [52] | A. N. Pettitt, A two-sample Anderson-Darling rank statistic, Biometrika, 63 (1976), 161-168. |
| [53] | S. Siegel, Nonparametric statistics, Am. Stat., 11 (1957), 13-19. |
| [54] | J. Zhang, L. Kurgan, SCRIBER: accurate and partner type-specific prediction of protein-binding residues from proteins sequences, Bioinformatics, 35 (2019), i343-i353. |
| [55] | J. Zhang, Z. Ma, L. Kurgan, Comprehensive review and empirical analysis of hallmarks of DNA-, RNA-and protein-binding residues in protein chains, Briefings Bioinf., 20 (2019), 1250-1268. |
| [56] |
G. Beliakov, G. Li, Improving the speed and stability of the k-nearest neighbors method, Pattern Recognit. Lett., 33 (2012), 1296-1301. doi: 10.1016/j.patrec.2012.02.016
|
| [57] | D. A. Pisner, D. M. Schnyer, Support vector machine, in Machine Learning, (2020), 101-121. |
| [58] | T. Calders, S. Verwer, Three naive bayes approaches for discrimination-free classification, in Data Mining and Knowledge Discovery, 21 (2010), 277-292. |
| [59] | A. L. Boulesteix, S. Janitza, J. Kruppa, I. R. König, Overview of random forest methodology and practical guidance with emphasis on computational biology and bioinformatics, in Wiley Interdisciplinary Reviews: Data Mining and Knowledge Discovery, 2 (2012), 493-507. |
| [60] | Y. Zhang, X. Zhang, A. N. Lane, T. W. M. Fan, J. Liu, Inferring gene regulatory networks of metabolic enzymes using gradient boosted trees, in IEEE journal of biomedical and health informatics, 24 (2019), 1528-1536. |
| [61] | B. Jassal, L. Matthews, G. Viteri, C. Gong, P. Lorente, A. Fabregat, et al., The reactome pathway knowledgebase, Nucleic Acids Res., 48 (2020), D498-D503. |
| [62] | J. Mistry, S. Chuguransky, L. Williams, M. Qureshi, G. A.Salazar, E. L.Sonnhammer, et al., Pfam: The protein families database in 2021, Nucleic Acids Res., 49 (2021), D412-D419. |
| [63] | H. Mi, D. Ebert, A. Muruganujan, C. Mills, L. P. Albou, T. Mushayamaha, et al., PANTHER version 16: a revised family classification, tree-based classification tool, enhancer regions and extensive API, Nucleic Acids Res., 49 (2021), D394-D403. |
 mbe-18-05-318-supplementary.pdf |
 |
| 1. | Fei Luo, Mingjie Shi, Junhao Guo, Yisen Cheng, Xusan Xu, Jieqing Zeng, Si Huang, Weijun Huang, Wenfeng Wei, Yajun Wang, Riling Chen, Guoda Ma, Association between the RETN -420C/G polymorphism and type 2 diabetes mellitus susceptibility: A meta-analysis of 23 studies, 2022, 13, 1664-2392, 10.3389/fendo.2022.1039919 |
Jian Zhang, Xingchen Liang, Feng Zhou, Bo Li, Yanling Li. TYLER, a fast method that accurately predicts cyclin-dependent proteins by using computation-based motifs and sequence-derived features[J]. Mathematical Biosciences and Engineering, 2021, 18(5): 6410-6429. doi: 10.3934/mbe.2021318
| Item | Normal range | Study subjects | P | |
| Control (n = 244) | T2DM (n = 305) | |||
| Male/female | 156/88 | 159/146 | 0.003 | |
| Age (years) | 51.5 ± 13.3 | 57.6 ± 11.2 | < 0.001 | |
| BMI (kg/m2) | 25.5 ± 5.5 | 25.4 ± 5.5 | 0.078 | |
| Fasting plasma glucose (AC) | 70–110 mg/dl | 105.2 ± 40.3 | 176.4 ± 70.4 | < 0.001 |
| Blood urea nitrogen (BUN) | 7–21 mg/dl | 15.0 ± 4.8 | 17.2 ± 7.8 | < 0.001 |
| Creatinine | 0.6–1.4 mg/dl | 1.1 ± 0.3 | 1.0 ± 0.5 | 0.066 |
| Systolic pressure (SP) | 120–140 mmHg | 123.7 ± 17.6 | 133.5 ± 18.6 | < 0.001 |
| Diastolic pressure (DP) | 70–90 mmHg | 78.4 ± 9.6 | 79.2 ± 11.5 | 0.521 |
| Cholesterol (CHO) | 125–240 mg/dl | 193.0 ± 37.5 | 198.8 ± 46.8 | 0.055 |
| High density lipoprotein-cholesterol (HDL-C) | > 35 mg/dl | 55.5 ± 38.2 | 47.8 ± 13.9 | < 0.001 |
| Triglyceride (TG) | 20–200 mg/dl | 150.7 ± 129.6 | 183.6 ± 129.6 | 0.004 |
| *Student's t test. †Data are presented as mean ± standard deviation. | ||||
DownLoad: CSV| Genotype/allele | Resistin -420C>G SNPs | P | |
| Control (n = 244) | T2DM (n = 305) | ||
| C/C | 70 (28.7%) | 124 (40.6%) | 0.01 |
| C/G | 127 (52.0%) | 139 (45.6%) | |
| G/G | 47 (19.3%) | 42 (13.8%) | |
| C | 267 (54.7%) | 387 (63.4%) | 0.002 |
| G | 221 (45.3%) | 223 (36.6%) | |
DownLoad: CSV| Item | Range | Control | T2DM | ||||||||
| n | C/C n (%) | C/G n (%) | G/G n (%) | P | n | C/C n (%) | C/G n (%) | G/G n (%) | P | ||
| BMI | ≥25 | 97 | 34 (35.1%) | 49 (50.5%) | 14 (14.4%) | 0.073 | 74 | 28 (37.8%) | 38 (51.4%) | 8 (10.8%) | 0.280 |
| < 25 | 124 | 29 (23.4%) | 65 (52.4%) | 30 (24.2%) | 54 | 23 (42.6%) | 21 (38.9%) | 10 (18.5%) | |||
| SP | ≥140 | 45 | 9 (20%) | 29 (64.4%) | 7 (15.6%) | 0.162 | 37 | 13 (35.1%) | 18 (48.7%) | 6 (16.2%) | 0.794 |
| < 140 | 175 | 53 (30.3%) | 85 (48.6%) | 37 (21.1%) | 57 | 24 (42.1%) | 25 (43.9%) | 8 (14%) | |||
| DP | ≥90 | 33 | 8 (24.2%) | 18 (54.6%) | 7 (21.2%) | 0.862 | 25 | 10 (40%) | 13 (52%) | 2 (8%) | 0.501 |
| < 90 | 187 | 54 (28.9%) | 96 (51.3%) | 37 (19.8%) | 69 | 27 (39.1%) | 30 (43.5%) | 12 (17.4%) | |||
| AC | ≥110 | 27 | 7 (26%) | 12 (44.4%) | 8 (29.6%) | 0.399 | 186 | 77 (41.4%) | 80 (43%) | 29 (15.6%) | 0.186 |
| < 110 | 194 | 56 (28.8%) | 102 (52.6%) | 36 (18.6%) | 19 | 4 (21.1%) | 10 (52.6%) | 5 (26.3%) | |||
| BUN | ≥25 | 2 | 0 | 2 (100%) | 0 | 0.388 | 21 | 7 (33.3%) | 11 (52.4%) | 3 (14.3%) | 0.634 |
| < 25 | 219 | 63 (28.8%) | 112 (51.1%) | 44 (20.1%) | 132 | 57 (43.2%) | 55 (41.7%) | 20 (15.1%) | |||
| CRE | ≥1.4 | 17 | 1 (5.9%) | 12 (70.6%) | 4 (23.5%) | 0.092 | 27 | 11 (40.8%) | 9 (33.3%) | 7 (25.9%) | 0.256 |
| < 1.4 | 203 | 62 (30.5%) | 101 (49.8%) | 40 (19.7%) | 163 | 63 (38.7%) | 76 (46.6%) | 24 (14.7%) | |||
| CHO | ≥240 | 21 | 4 (19.1%) | 14 (66.7%) | 3 (14.2%) | 0.358 | 24 | 13 (54.2%) | 6 (25%) | 5 (20.8%) | 0.103 |
| < 240 | 199 | 58 (29.1%) | 100 (50.3%) | 41 (20.6%) | 175 | 64 (36.6%) | 84 (48%) | 27 (15.4%) | |||
| HDL-C | > 35 | 196 | 60 (30.6%) | 100 (51%) | 36 (18.4%) | 0.088 | 131 | 52 (39.7%) | 58 (44.3%) | 21 (16%) | 0.390 |
| ≤35 | 25 | 3 (12%) | 14 (56%) | 8 (32%) | 37 | 12 (32.4%) | 21 (56.8%) | 4 (10.8%) | |||
| TG | ≥200 | 51 | 14 (27.5%) | 24 (47.1%) | 13 (25.4%) | 0.521 | 59 | 26 (44.1%) | 24 (40.7%) | 9 (15.2%) | 0.557 |
| < 200 | 169 | 48 (28.4%) | 90 (53.3%) | 31 (18.3%) | 139 | 50 (36%) | 66 (47.5%) | 23 (16.5%) | |||
DownLoad: CSV| Genotype | Control | T2DM | P | ||
| n (107) | Resistin (ng/mL) | n (58) | Resistin (ng/mL) | ||
| C/C | 16 | 2.50 ± 0.44 | 22 | 3.95 ± 0.80 | 0.044 |
| C/G | 54 | 3.94 ± 0.53 | 24 | 4.31 ± 0.88 | |
| G/G | 37 | 2.56 ± 0.43 | 12 | 4.88 ± 2.31 | |
| Resistin levels secreted from the ConA-activated PBMCs from 107 control and 58 diabetic subjects were analyzed. | |||||
DownLoad: CSV| Population/ Subjects | n | SNP | allele | Association | Ref. | |||
| C/C | C/G | G/G | C | G | ||||
| Finnish | ||||||||
| Control | 409 | 599 (73.2%) | 219 (26.7%) | insulin resistance | [17] | |||
| T2DM | 781 | 1141 (73.0%) | 423 (27.0%) | |||||
| Canadian | ||||||||
| Control | 411 | 212 (51.6%) | 169 (41.1%) | 30 (7.3%) | 593 (72.1%) | 229 (27.9%) | BMI | [15] |
| T2DM | 179 | 90 (50.3%) | 78 (43.6%) | 11 (6.1%) | 258 (72.1%) | 100 (27.9%) | ||
| Scandinavian | ||||||||
| Control | 433 | 236 (54.5%) | 156 (36.0%) | 41 (9.5%) | 628 (72.5%) | 238 (27.5%) | [15] | |
| T2DM | 452 | 238 (52.7%) | 170 (37.6%) | 44 (9.7%) | 646 (71.5%) | 258 (28.5%) | ||
| European-derived Brazilian | ||||||||
| Control | 251 | 125 (49.8%) | 101 (40.2%) | 25 (10.0%) | 351 (69.9%) | 151 (30.1%) | BMI waist circumference | [19] |
| Overweight & obese | 334 | 182 (54.5%) | 122 (36.5%) | 30 (9.0%) | 486 (72.8%) | 182 (27.2%) | ||
| Korean | ||||||||
| Control | 173 | 89 (51.5%) | 63 (36.4%) | 21 (12.1%) | 241 (69.7%) | 105 (30.3%) | resistin level | [6] |
| T2DM | 411 | 194 (47.2%) | 163 (39.7%) | 54 (13.1%) | 551 (67.0%) | 271 (33.0%) | ||
| Japanese | ||||||||
| Control | 564 | 247 (43.8%) | 269 (47.7%) | 48 (8.5%) | 763 (67.6%) | 365 (32.4%) | T2DM | [22] |
| T2DM | 546 | 216 (39.6%) | 254 (46.5%) | 76 (13.9%) | 686 (62.8%) | 406 (37.2%) | ||
| Japanese | ||||||||
| Control | 2,502 | 1,080 (43.2%) | 1,123 (44.9%) | 299 (11.9%) | 3,283 (65.6%) | 1,721 (34.4%) | young T2DM | [23] |
| T2DM | 2,610 | 1,169 (44.9%) | 1,144 (43.8%) | 297 (11.4%) | 3,482 (66.7%) | 1,738 (33.3%) | ||
| Taiwanese | ||||||||
| Control | 244 | 70 (28.7%) | 127 (52.0%) | 47 (19.3%) | 267 (54.7%) | 221 (45.3%) | T2DM resistin level | this study |
| T2DM | 305 | 124 (40.6%) | 139 (45.6%) | 42 (13.8%) | 387 (63.4%) | 223 (36.6%) | ||
| Numbers in parenthesis of population indicated the number of study subjects in each study. | ||||||||
DownLoad: CSV| No | Population/Subjects | n | SNP | Association | Ref. | ||
| Serum resistin | T2DM | others | |||||
| Meta-analysis | |||||||
| 1 | Control | 5,959 | -420C>G | – | – | [26] | |
| T2DM | 5,935 | ||||||
| 2 | Control | 529 | -638G>A | + | – | [29] | |
| T2DM | 529 | -420C>G | – | – | |||
| Chinese | |||||||
| 3 | Control | 370 | -420C>G | – | [28] | ||
| T2DM | 318 | -394C>G | – | ||||
| 4 | Non-diabetic subjects | 624 | -420C>G | + | insulin resistance | [24] | |
| +62G>A | glycemia | ||||||
| Japanese | |||||||
| 5 | Control | 286 | -420C>G | + | stroke | [30] | |
| T2DM | 349 | ||||||
| 6 | Community subjects | 2,077 | -420C>G | + | synergistically with PPAR P12A | [31] | |
| 7 | Control | 2,502 | -420C>G | – | young T2DM onset | [23] | |
| T2DM | 2,610 | ||||||
| 8 | Community subjects | 2,078 | -420C>G | + | insulin resistance, low HDL high CRP | [37] | |
| 9 | Obese | 60 | -638G>A | + | [38] | ||
| -420C>G | + | ||||||
| 10 | controls | 157 | -420C>G | + | [32] | ||
| T2DM | 198 | ||||||
| 11 | Control | 406 | -420C>G | + | + | [22] | |
| T2DM | 397 | ||||||
| Thais | |||||||
| 12 | Control | 105 | -420C>G | – | [39] | ||
| T2DM | 95 | +299G>A | + | + | |||
| Korean | |||||||
| 13 | Control | 173 | -537A>C | + | [6] | ||
| T2DM | 411 | -420C>G | + | ||||
DownLoad: CSV| Item | Normal range | Study subjects | P | |
| Control (n = 244) | T2DM (n = 305) | |||
| Male/female | 156/88 | 159/146 | 0.003 | |
| Age (years) | 51.5 ± 13.3 | 57.6 ± 11.2 | < 0.001 | |
| BMI (kg/m2) | 25.5 ± 5.5 | 25.4 ± 5.5 | 0.078 | |
| Fasting plasma glucose (AC) | 70–110 mg/dl | 105.2 ± 40.3 | 176.4 ± 70.4 | < 0.001 |
| Blood urea nitrogen (BUN) | 7–21 mg/dl | 15.0 ± 4.8 | 17.2 ± 7.8 | < 0.001 |
| Creatinine | 0.6–1.4 mg/dl | 1.1 ± 0.3 | 1.0 ± 0.5 | 0.066 |
| Systolic pressure (SP) | 120–140 mmHg | 123.7 ± 17.6 | 133.5 ± 18.6 | < 0.001 |
| Diastolic pressure (DP) | 70–90 mmHg | 78.4 ± 9.6 | 79.2 ± 11.5 | 0.521 |
| Cholesterol (CHO) | 125–240 mg/dl | 193.0 ± 37.5 | 198.8 ± 46.8 | 0.055 |
| High density lipoprotein-cholesterol (HDL-C) | > 35 mg/dl | 55.5 ± 38.2 | 47.8 ± 13.9 | < 0.001 |
| Triglyceride (TG) | 20–200 mg/dl | 150.7 ± 129.6 | 183.6 ± 129.6 | 0.004 |
| *Student's t test. †Data are presented as mean ± standard deviation. | ||||
| Genotype/allele | Resistin -420C>G SNPs | P | |
| Control (n = 244) | T2DM (n = 305) | ||
| C/C | 70 (28.7%) | 124 (40.6%) | 0.01 |
| C/G | 127 (52.0%) | 139 (45.6%) | |
| G/G | 47 (19.3%) | 42 (13.8%) | |
| C | 267 (54.7%) | 387 (63.4%) | 0.002 |
| G | 221 (45.3%) | 223 (36.6%) | |
| Item | Range | Control | T2DM | ||||||||
| n | C/C n (%) | C/G n (%) | G/G n (%) | P | n | C/C n (%) | C/G n (%) | G/G n (%) | P | ||
| BMI | ≥25 | 97 | 34 (35.1%) | 49 (50.5%) | 14 (14.4%) | 0.073 | 74 | 28 (37.8%) | 38 (51.4%) | 8 (10.8%) | 0.280 |
| < 25 | 124 | 29 (23.4%) | 65 (52.4%) | 30 (24.2%) | 54 | 23 (42.6%) | 21 (38.9%) | 10 (18.5%) | |||
| SP | ≥140 | 45 | 9 (20%) | 29 (64.4%) | 7 (15.6%) | 0.162 | 37 | 13 (35.1%) | 18 (48.7%) | 6 (16.2%) | 0.794 |
| < 140 | 175 | 53 (30.3%) | 85 (48.6%) | 37 (21.1%) | 57 | 24 (42.1%) | 25 (43.9%) | 8 (14%) | |||
| DP | ≥90 | 33 | 8 (24.2%) | 18 (54.6%) | 7 (21.2%) | 0.862 | 25 | 10 (40%) | 13 (52%) | 2 (8%) | 0.501 |
| < 90 | 187 | 54 (28.9%) | 96 (51.3%) | 37 (19.8%) | 69 | 27 (39.1%) | 30 (43.5%) | 12 (17.4%) | |||
| AC | ≥110 | 27 | 7 (26%) | 12 (44.4%) | 8 (29.6%) | 0.399 | 186 | 77 (41.4%) | 80 (43%) | 29 (15.6%) | 0.186 |
| < 110 | 194 | 56 (28.8%) | 102 (52.6%) | 36 (18.6%) | 19 | 4 (21.1%) | 10 (52.6%) | 5 (26.3%) | |||
| BUN | ≥25 | 2 | 0 | 2 (100%) | 0 | 0.388 | 21 | 7 (33.3%) | 11 (52.4%) | 3 (14.3%) | 0.634 |
| < 25 | 219 | 63 (28.8%) | 112 (51.1%) | 44 (20.1%) | 132 | 57 (43.2%) | 55 (41.7%) | 20 (15.1%) | |||
| CRE | ≥1.4 | 17 | 1 (5.9%) | 12 (70.6%) | 4 (23.5%) | 0.092 | 27 | 11 (40.8%) | 9 (33.3%) | 7 (25.9%) | 0.256 |
| < 1.4 | 203 | 62 (30.5%) | 101 (49.8%) | 40 (19.7%) | 163 | 63 (38.7%) | 76 (46.6%) | 24 (14.7%) | |||
| CHO | ≥240 | 21 | 4 (19.1%) | 14 (66.7%) | 3 (14.2%) | 0.358 | 24 | 13 (54.2%) | 6 (25%) | 5 (20.8%) | 0.103 |
| < 240 | 199 | 58 (29.1%) | 100 (50.3%) | 41 (20.6%) | 175 | 64 (36.6%) | 84 (48%) | 27 (15.4%) | |||
| HDL-C | > 35 | 196 | 60 (30.6%) | 100 (51%) | 36 (18.4%) | 0.088 | 131 | 52 (39.7%) | 58 (44.3%) | 21 (16%) | 0.390 |
| ≤35 | 25 | 3 (12%) | 14 (56%) | 8 (32%) | 37 | 12 (32.4%) | 21 (56.8%) | 4 (10.8%) | |||
| TG | ≥200 | 51 | 14 (27.5%) | 24 (47.1%) | 13 (25.4%) | 0.521 | 59 | 26 (44.1%) | 24 (40.7%) | 9 (15.2%) | 0.557 |
| < 200 | 169 | 48 (28.4%) | 90 (53.3%) | 31 (18.3%) | 139 | 50 (36%) | 66 (47.5%) | 23 (16.5%) | |||
| Genotype | Control | T2DM | P | ||
| n (107) | Resistin (ng/mL) | n (58) | Resistin (ng/mL) | ||
| C/C | 16 | 2.50 ± 0.44 | 22 | 3.95 ± 0.80 | 0.044 |
| C/G | 54 | 3.94 ± 0.53 | 24 | 4.31 ± 0.88 | |
| G/G | 37 | 2.56 ± 0.43 | 12 | 4.88 ± 2.31 | |
| Resistin levels secreted from the ConA-activated PBMCs from 107 control and 58 diabetic subjects were analyzed. | |||||
| Population/ Subjects | n | SNP | allele | Association | Ref. | |||
| C/C | C/G | G/G | C | G | ||||
| Finnish | ||||||||
| Control | 409 | 599 (73.2%) | 219 (26.7%) | insulin resistance | [17] | |||
| T2DM | 781 | 1141 (73.0%) | 423 (27.0%) | |||||
| Canadian | ||||||||
| Control | 411 | 212 (51.6%) | 169 (41.1%) | 30 (7.3%) | 593 (72.1%) | 229 (27.9%) | BMI | [15] |
| T2DM | 179 | 90 (50.3%) | 78 (43.6%) | 11 (6.1%) | 258 (72.1%) | 100 (27.9%) | ||
| Scandinavian | ||||||||
| Control | 433 | 236 (54.5%) | 156 (36.0%) | 41 (9.5%) | 628 (72.5%) | 238 (27.5%) | [15] | |
| T2DM | 452 | 238 (52.7%) | 170 (37.6%) | 44 (9.7%) | 646 (71.5%) | 258 (28.5%) | ||
| European-derived Brazilian | ||||||||
| Control | 251 | 125 (49.8%) | 101 (40.2%) | 25 (10.0%) | 351 (69.9%) | 151 (30.1%) | BMI waist circumference | [19] |
| Overweight & obese | 334 | 182 (54.5%) | 122 (36.5%) | 30 (9.0%) | 486 (72.8%) | 182 (27.2%) | ||
| Korean | ||||||||
| Control | 173 | 89 (51.5%) | 63 (36.4%) | 21 (12.1%) | 241 (69.7%) | 105 (30.3%) | resistin level | [6] |
| T2DM | 411 | 194 (47.2%) | 163 (39.7%) | 54 (13.1%) | 551 (67.0%) | 271 (33.0%) | ||
| Japanese | ||||||||
| Control | 564 | 247 (43.8%) | 269 (47.7%) | 48 (8.5%) | 763 (67.6%) | 365 (32.4%) | T2DM | [22] |
| T2DM | 546 | 216 (39.6%) | 254 (46.5%) | 76 (13.9%) | 686 (62.8%) | 406 (37.2%) | ||
| Japanese | ||||||||
| Control | 2,502 | 1,080 (43.2%) | 1,123 (44.9%) | 299 (11.9%) | 3,283 (65.6%) | 1,721 (34.4%) | young T2DM | [23] |
| T2DM | 2,610 | 1,169 (44.9%) | 1,144 (43.8%) | 297 (11.4%) | 3,482 (66.7%) | 1,738 (33.3%) | ||
| Taiwanese | ||||||||
| Control | 244 | 70 (28.7%) | 127 (52.0%) | 47 (19.3%) | 267 (54.7%) | 221 (45.3%) | T2DM resistin level | this study |
| T2DM | 305 | 124 (40.6%) | 139 (45.6%) | 42 (13.8%) | 387 (63.4%) | 223 (36.6%) | ||
| Numbers in parenthesis of population indicated the number of study subjects in each study. | ||||||||
| No | Population/Subjects | n | SNP | Association | Ref. | ||
| Serum resistin | T2DM | others | |||||
| Meta-analysis | |||||||
| 1 | Control | 5,959 | -420C>G | – | – | [26] | |
| T2DM | 5,935 | ||||||
| 2 | Control | 529 | -638G>A | + | – | [29] | |
| T2DM | 529 | -420C>G | – | – | |||
| Chinese | |||||||
| 3 | Control | 370 | -420C>G | – | [28] | ||
| T2DM | 318 | -394C>G | – | ||||
| 4 | Non-diabetic subjects | 624 | -420C>G | + | insulin resistance | [24] | |
| +62G>A | glycemia | ||||||
| Japanese | |||||||
| 5 | Control | 286 | -420C>G | + | stroke | [30] | |
| T2DM | 349 | ||||||
| 6 | Community subjects | 2,077 | -420C>G | + | synergistically with PPAR P12A | [31] | |
| 7 | Control | 2,502 | -420C>G | – | young T2DM onset | [23] | |
| T2DM | 2,610 | ||||||
| 8 | Community subjects | 2,078 | -420C>G | + | insulin resistance, low HDL high CRP | [37] | |
| 9 | Obese | 60 | -638G>A | + | [38] | ||
| -420C>G | + | ||||||
| 10 | controls | 157 | -420C>G | + | [32] | ||
| T2DM | 198 | ||||||
| 11 | Control | 406 | -420C>G | + | + | [22] | |
| T2DM | 397 | ||||||
| Thais | |||||||
| 12 | Control | 105 | -420C>G | – | [39] | ||
| T2DM | 95 | +299G>A | + | + | |||
| Korean | |||||||
| 13 | Control | 173 | -537A>C | + | [6] | ||
| T2DM | 411 | -420C>G | + | ||||
